In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin

In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin

High-mobility group box 1 (HMGB1) is a nuclear and cytosolic protein that is released during tissue damage from immune and non-immune cells — including microglia and neurons. HMGB1 can contribute to progression of numerous chronic inflammatory and autoimmune diseases which is mediated in part by int...

Full description

Bibliographic Details
Main Authors: Matteo Santoro, Walter Maetzler, Petros Stathakos, Heather L. Martin, Markus A. Hobert, Tim W. Rattay, Thomas Gasser, John V. Forrester, Daniela Berg, Kevin J. Tracey, Gernot Riedel, Peter Teismann
Format: Article
Language:English
Published: Elsevier 2016-07-01
Series:Neurobiology of Disease
Subjects:
Parkinson's disease
MPTP
High-mobility group box 1
receptor for advanced glycation endproducts
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996116300407

Internet

http://www.sciencedirect.com/science/article/pii/S0969996116300407

Similar Items